Navigation Links
ETHICON Launches the Latest Innovation in Hernia Repair Platform; PROCEED(TM) Ventral Patch (PVP(TM) Device)
Date:12/16/2008

New System Capitalizes on Innovative Materials and Technology

SOMERVILLE, N.J., Dec. 16 /PRNewswire/ -- ETHICON, INC, a global medical device company, today announced the launch of the PROCEED Ventral Patch (PVP Device), the latest addition to its family of hernia products. PVP Device is the first and only umbilical hernia repair device featuring lighter-weight mesh and exclusive, absorbable deployment technology. It is indicated for use in umbilical, epigastric, small ventral and trocar site hernias.

Hernias are extremely common. Umbilical hernias occur near the belly button or navel, which has a natural weakness from the blood vessels of the umbilical cord. These hernias may occur in infants at or just after birth, and may resolve at 3 or 4 years of age. However, the area of weakness can persist throughout life and can occur in men, women, and children at any time. In adults, umbilical hernias will not resolve and may progressively worsen over time. They are sometimes caused by abdominal pressure due to being overweight, excessive coughing, or pregnancy.

The PROCEED Ventral Patch is a sterile, self-expanding, partially absorbable, flexible mesh device that utilizes the proven design of PROCEED Surgical Mesh. The unique product design offers surgeons secure and stable deployment,(1) strength without ePTFE (expanded polytetrafluoroethylene),(2) and a macroporous / partially absorbable construction.(3) The PVP Device is available in small (4.3 cm) and medium (6.4 cm) sizes.

Dr. Carl Doerhoff, the first surgeon to implant the PVP Device in a human patient in the US, stated, "I'm very excited about the new technology advancements present in the PVP Device. Knowing that the product is flexible and partially absorbable for a greater likelihood of long-term patient comfort is an added benefit."

The PROCEED Ventral Patch is made by ETHICON, INC., a Johnson & Johnson company. ETHICON continues Johnson & Johnson's 100-year commitment to wound care today with innovative products for general surgery, wound management, women's health and urology, and wound closure. For more information about ETHICON visit www.ethicon.com.

(1) Data on file. ETHICON, INC.

(2) Welty G, Klinge U, Klosterhalfen B, Kasperk R, Schumpelick V. Functional impairment and complaints following incisional hernia repair with different polypropylene meshes. Hernia. 2001;5(3):142-147.

(3) Harrell AG, Novitsky YW, Cristiano JA, et al. Prospective histologic evaluation of intra-abdominal prosthetics four months after implantation in a rabbit model. Surg Endosc. 2007;21:1170-1174.

    Contact:    Michelle Bauman
                (908) 218-2463
                ETHICON, Inc.
                mbauman@its.jnj.com


'/>"/>
SOURCE ETHICON, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
2. ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business
3. ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners
4. Board-Certified Bariatric Surgeon, Trace Curry, MD Places First Next-Generation Ethicon Endo-Surgery REALIZE™ Adjustable Gastric Band-C in Ohio
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. UPMC Health Plan Launches New Personal Health Record
7. HealthInsuranceFinders.com Launches Video Contest for Young Directors
8. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
9. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
10. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
11. Mannatech Launches Phase One of New Sales and Training Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: